The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleucel (Tecelra ®, also known as afami-cel) for the treatment of adults with a rare ...
Letetresgene autoleucel (lete-cel) showed a 42% response rate in a phase 2 trial for synovial sarcoma and myxoid/round cell liposarcoma. The trial included 64 patients, with 41% response in synovial ...
Advanced and metastatic sarcomas remain among the most difficult malignancies to treat. Challenges to progress include their rarity at 1% of all solid cancers, histologic and molecular diversity with ...
The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma. The study investigators from City of Hope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback